Attachment No. 5 - Additional Questions Answers_.pdf
PDF 221 KB Posted
- Attached to
- FY23 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory Science
- Solicitation number
- FDABAA-23-00123
About this file
This document contains questions and answers related to the FY23 FDA Broad Agency Announcement for Advanced Research and Development of Regulatory Science. The Broad Agency Announcement solicits proposals to support regulatory science and innovation through basic and applied research and development. Key details include that offerors must submit individual proposals for each research area, the government retains limited or unlimited rights to intellectual property with rights negotiable prior to award, and timelines are proposed by applicants. Prior recipients can be found on the Federal Procurement Data System website. Cost is to be proposed and profit must be fair and reasonable as determined by the contracting officer. Guidance on allowable cost rates can be found in the FAR. The document provides clarification on the scope of research categories and updates made in Amendment 2.
View the file
Other files
Show all 12
On GovTribe
Work with this file
- Download the original file
- Contacts named in this file
- Similar government files
- Ask GovTribe AI about this file
Text version
Attachment No: 5 Questions & Answers
Solicitation No: FDABAA-23-00123 – Amendment # 2
1.
Solicitation Section/Subsection Number: Sol Doc_FDABAA-23-00123
Question:
What is the funding amount for FDABAA-23-00123?
Government Response:
(For Government use only)
We do not have a finalized number at this time, and probably not until 3rd quarter.
2.
Question:
Can offerors submit a single proposal that is responsive to multiple Primary Research Areas?
Government Response:
Offerors required to submit individual proposal of each research area.
3.
Who owns the intellectual property once the research is generated/completed?
Government Response:
Generally the government retains limited use rights, but unlimited rights for the government or a hybrid can be negotiated prior to contract award.
4.
Question:
What time frame is the FDA looking for projects (1, 2, 5, etc.) or is it to the discretion of the applicant?
Government Response:
Timelines are to be proposed by the applicant.
5.
Question:
Based on what I have read, there is no funding limitation specified by the BAA mechanism: however, individual FDA offices are limited by available budgets for research. Do you know what the funding limitation is here or it is the discretion of the applicant to determine.
Government Response:
(For Government use only)
Overall funding is determined by the agency, and the funding at the contract level is determined by the proposal and any negotiations that occur.
6.
How do I find prior recipients of this award?
Prior recipients can find in “Federal Procurement Data System” at the following link.
https://www.fpds.gov/fpdsng_cms/index.php/en/
7.
What is the funding vehicle of this application?
Proposal dependant
8.
Question:
I unfortunately missed the webinar. I am a current participant, and I also intend to submit a couple of white papers this year - would you please share with me the webinar presentation?
Also, was the session recorded? If so, is there a link available to the recorded session?
Government Response:
(For Government use only) https://fda.zoomgov.com/rec/share/I3aM_Gjz7lAb3KVJmJI1lYV8Mqo3aGgL9_oI3jx6fFirkV z8Z9xKvxKWV4Pv5AJr.ubCqbg7TUd7XBSS2?startTime=1670338801000 https://www.fpds.gov/fpdsng_cms/index.php/en/
9.
Question:
We request clarification about the scope of the following research category on page 20 of the FDA BAA solicitation document:
• FDA charge: I. Modernize development and evaluation of FDA-regulated products
• Focus area: I. Approaches to Incorporate Patient and Consumer Input
• Sub-focus area: 2. Devices
• Research category: a. Explore human factors engineering principles in device and combination product design and review
Specifically, does the above research category include any type of medical device, only medications, or both in its scope?
Government Response:
Updated in amendment 00002
10.
Are the cost rules based on internal rates?
Cost is based as proposed.
11.
Where can I can I find clarity on the cost rules as the FDA BAA announcement is not clear on the rates?
https://www.acquisition.gov/far/subpart-16.3
12.
Question:
Are you able to provide guidance on what profit we can add?
Government Response:
Profit must be fair and reasonable as determined by a contracting officer.
13.
Who retains the rights to the models that we create using our software?
Please see question 3.
End of Questions & Answers.
| Attachment No: 5 |
| Questions & Answers |
| Solicitation No: FDABAA-23-00123 – Amendment # 2 |
File details come from the government source that posted it. Updated .